226 related articles for article (PubMed ID: 11707844)
1. Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells.
Pichert G; Schmitz SF; Hess U; Cerny T; Cogliatti SB; Betticher D; Stupp R; Schmitter D; Stahel RA; Ghielmini M
Clin Lymphoma; 2001 Mar; 1(4):293-7. PubMed ID: 11707844
[TBL] [Abstract][Full Text] [Related]
2. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
3. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
5. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
Foran JM; Gupta RK; Cunningham D; Popescu RA; Goldstone AH; Sweetenham JW; Pettengell R; Johnson PW; Bessell E; Hancock B; Summers K; Hughes J; Rohatiner AZ; Lister TA
Br J Haematol; 2000 Apr; 109(1):81-8. PubMed ID: 10848785
[TBL] [Abstract][Full Text] [Related]
6. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.
Hirt C; Schüler F; Kiefer T; Schwenke C; Haas A; Niederwieser D; Neser S; Assmann M; Srock S; Rohrberg R; Dachselt K; Leithäuser M; Rabkin CS; Herold M; Dölken G
Br J Haematol; 2008 May; 141(5):631-40. PubMed ID: 18422779
[TBL] [Abstract][Full Text] [Related]
7. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
8. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma.
Mandigers CM; Meijerink JP; Mensink EJ; Tönnissen EL; Hebeda KM; Bogman MJ; Raemaekers JM;
Blood; 2001 Aug; 98(4):940-4. PubMed ID: 11493436
[TBL] [Abstract][Full Text] [Related]
9. The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21).
Ha CS; Tucker SL; Lee MS; McLaughlin P; Cabanillas F; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):727-32. PubMed ID: 11172955
[TBL] [Abstract][Full Text] [Related]
10. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
11. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
Czuczman MS; Grillo-López AJ; McLaughlin P; White CA; Saleh M; Gordon L; LoBuglio AF; Rosenberg J; Alkuzweny B; Maloney D
Ann Oncol; 2001 Jan; 12(1):109-14. PubMed ID: 11249036
[TBL] [Abstract][Full Text] [Related]
12. Follicular lymphoma: 2012 update on diagnosis and management.
Freedman A
Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
[TBL] [Abstract][Full Text] [Related]
13. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
[TBL] [Abstract][Full Text] [Related]
14. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
Ghielmini M; Schmitz SF; Cogliatti SB; Pichert G; Hummerjohann J; Waltzer U; Fey MF; Betticher DC; Martinelli G; Peccatori F; Hess U; Zucca E; Stupp R; Kovacsovics T; Helg C; Lohri A; Bargetzi M; Vorobiof D; Cerny T
Blood; 2004 Jun; 103(12):4416-23. PubMed ID: 14976046
[TBL] [Abstract][Full Text] [Related]
15. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
16. De novo acute B cell leukemia/lymphoma with t(14;18).
Stamatoullas A; Buchonnet G; Lepretre S; Lenain P; Lenormand B; Duval C; Callat MP; Gaulard P; Bastard C; Tilly H
Leukemia; 2000 Nov; 14(11):1960-6. PubMed ID: 11069032
[TBL] [Abstract][Full Text] [Related]
17. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
Kennedy GA; Blum R; McCormack C; Prince HM
Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
[TBL] [Abstract][Full Text] [Related]
18. Follicular lymphoma: 2014 update on diagnosis and management.
Freedman A
Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887
[TBL] [Abstract][Full Text] [Related]
19. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab.
Buckstein RJ; Rimrie K; Pennell N; Spaner D; Hewitt K; Berinstein NL
Leuk Lymphoma; 2001 Apr; 41(3-4):451-5. PubMed ID: 11378562
[TBL] [Abstract][Full Text] [Related]
20. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Colombat P; Salles G; Brousse N; Eftekhari P; Soubeyran P; Delwail V; Deconinck E; Haïoun C; Foussard C; Sebban C; Stamatoullas A; Milpied N; Boué F; Taillan B; Lederlin P; Najman A; Thièblemont C; Montestruc F; Mathieu-Boué A; Benzohra A; Solal-Céligny P
Blood; 2001 Jan; 97(1):101-6. PubMed ID: 11133748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
